Key Takeaways
- • Violet Therapeutics closes $4.75M seed extension led by Lifespan Vision Ventures, with co-investors including Dementia Discovery Fund, UTEC, Ono Venture Investment, and Mass General Brigham Ventures, positioning the company to advance its lead neurodegeneration program toward clinical development.
- • Violet's proprietary CONNECT platform targets synaptic loss, a primary driver of cognitive decline in Alzheimer's disease and neurodegenerative conditions, by systematically mapping disease-relevant cell-to-cell signaling interactions in the brain to identify actionable therapeutic pathways.
- • Lead program targets EphB3 for glial-mediated synaptic preservation and repair, with funding earmarked for IND-enabling activities to move the small molecule candidate toward regulatory filing.
- • LVV brings board-level expertise in aging biology and cognition therapeutics, with Altar Munis from the firm joining as board observer, signaling investor confidence in the company's scientific approach and commercial potential within the growing neurodegenerative disease market.
Summary
Lifespan Vision Ventures has led a $4.75 million seed extension financing round for Violet Therapeutics, a preclinical-stage biotechnology company focused on developing first-in-class therapies for neurodegenerative disease. The Cambridge-based firm has assembled a syndicate of specialized life sciences investors, including Dementia Discovery Fund, UTEC (University of Tokyo Edge Capital Partners), Ono Venture Investment, and Mass General Brigham Ventures, reflecting broad institutional confidence in the company's therapeutic platform and scientific direction.
Violet's core asset is its proprietary CONNECT platform, which maps disease-relevant cell-to-cell signaling interactions in the brain to identify therapeutically actionable pathways driving neuroinflammation, neurodegeneration, and synaptic loss. The company's lead program targets EphB3 and is designed to address synaptic loss—described as one of the strongest predictors of cognitive decline in Alzheimer's disease and related conditions—through glial-mediated synaptic preservation and repair mechanisms. The financing will fund IND-enabling activities to advance this small molecule candidate toward clinical development.
Altar Munis, Associate at Lifespan Vision Ventures, emphasized the strategic value of Violet's approach, noting that the CONNECT platform provides "a systematic way to uncover how glial signaling contributes to synaptic dysfunction." Meredith Fisher, CEO of Violet and Partner at Mass General Brigham Ventures, characterized LVV's participation as bringing "deep sector expertise in technologies that will impact diseases of aging and cognition" while adding valuable board perspective. Munis will join Violet's board as an observer, strengthening the operational and strategic alignment between investor and company as the firm progresses toward the clinic.
The round underscores continued institutional appetite for precision neurodegeneration therapeutics targeting specific pathological mechanisms rather than broad symptomatic approaches. Violet's focus on synaptic preservation positions it within a growing segment of aging biology therapeutics, aligning with LVV's stated investment thesis around healthspan extension and cognitive preservation across aging populations.
Violet's core asset is its proprietary CONNECT platform, which maps disease-relevant cell-to-cell signaling interactions in the brain to identify therapeutically actionable pathways driving neuroinflammation, neurodegeneration, and synaptic loss. The company's lead program targets EphB3 and is designed to address synaptic loss—described as one of the strongest predictors of cognitive decline in Alzheimer's disease and related conditions—through glial-mediated synaptic preservation and repair mechanisms. The financing will fund IND-enabling activities to advance this small molecule candidate toward clinical development.
Altar Munis, Associate at Lifespan Vision Ventures, emphasized the strategic value of Violet's approach, noting that the CONNECT platform provides "a systematic way to uncover how glial signaling contributes to synaptic dysfunction." Meredith Fisher, CEO of Violet and Partner at Mass General Brigham Ventures, characterized LVV's participation as bringing "deep sector expertise in technologies that will impact diseases of aging and cognition" while adding valuable board perspective. Munis will join Violet's board as an observer, strengthening the operational and strategic alignment between investor and company as the firm progresses toward the clinic.
The round underscores continued institutional appetite for precision neurodegeneration therapeutics targeting specific pathological mechanisms rather than broad symptomatic approaches. Violet's focus on synaptic preservation positions it within a growing segment of aging biology therapeutics, aligning with LVV's stated investment thesis around healthspan extension and cognitive preservation across aging populations.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.